The technology was developed in the laboratory of Andrew Lever at the University of Cambridge. Following the acquisition of the Cell Genesys’s lentiviral patent portfolio in 2007 by
Under the terms of this non-exclusive agreement, Hydromer will supply its proprietary and patented Hydromer hydrophilic coatings for use on various Pebax plastic neurovascular and cardiovascular catheters. This
On admission to the trial, patients were randomized on a two-to-one ratio into the treatment versus control groups with 26 patients receiving MyoCell therapy and 14 patients in
The GeneSys system is claimed to be the first on the market to offer a fully automated approach for newborn screening while providing positive identification for all major
The pharmacokinetic study was conducted in healthy human volunteers and compared the drug exposure profile of arbaclofen, under both fasted and fed conditions, following a single oral administration
Initially, clinical results for three different doses of the active ingredient 5-aminolevulinic acid (ALA) and placebo are compared. Following the treatment and two-month observation of 80 patients enrolled
The assets consisted of, rifalazil, a Phase II antibiotic, a library of novel rifamycin compounds, and a clinical stage superoxide dismutase mimetic (SODm) and a library of SODm
The validation of the marketing authorization application (MAA) for Xyotax initiates the marketing approval review process, which generally takes 15 to 18 months. The EMEA agreed that switching
Advanced Pain Therapeutics (APT), a new strategic development company formed by Cato Research, Advanced Targeting Systems (ATS), and Cato BioVentures, the venture capital affiliate of Cato Research, obtained
Droperidol (to be branded Xomolix) is a injectable drug, indicated for the prevention and treatment of post-operative nausea and vomiting in adults and, as a second line, in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.